Carregant...

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacokinet
Autors principals: Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8249270/
https://ncbi.nlm.nih.gov/pubmed/33709296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-021-01006-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!